DGAP-News: BioCrea GmbH: BioCrea Announces Upcoming

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: BioCrea GmbH: BioCrea Announces Upcoming Presentations at Leading International Conferences

DGAP-News: BioCrea GmbH / Key word(s): Conference BioCrea GmbH: BioCrea Announces Upcoming Presentations at Leading International Conferences 24.09.2014 / 09:00 --------------------------------------------------------------------- BioCrea Announces Upcoming Presentations at Leading International Conferences "On target with rapid acting antidepressants" Radebeul, Germany, September 24, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that Chief Executive Officer, Dr. Tom Kronbach, will present at the following three international life sciences conferences over the coming months. Dr. Tom Kronbach will be presenting: "On target with rapid acting antidepressants (RAAD)" at: The 14th Annual Biotech in Europe Forum, September 30 - October 1, 2014: Basel, Switzerland www.sachsforum.com Corporate presentation on September 30, 2014 at 11:00-11:15 CET in the Lima room and The Neuroscience Panel September 30, 2014 at 15:30-16:30 CET European Partnering and Investment Conference (EPIC), October 2, 2014: London, UK www.epicbiotech.com Corporate presentation on October 2, 2014 at 11:30 BST in the Maynard 1 room Therapeutic Area Partnerships (TAP), November 19 - 21, 2014: Boston, USA www.iirusa.com/therapeuticareapartnership Date and time of presentation to be confirmed "It is an exciting time to be presenting the BioCrea story and our lead program to three eminent international specialist audiences. In particular, we will focus on our advanced NMDA receptor 2B drug candidates for treatment-resistant depression," said Dr. Tom Kronbach, CEO of BioCrea, in the run-up to the events. For updates on these conferences please also visit our website: http://www.biocrea.com/news/events/ About the 14th Annual Biotech in Europe Forum The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe's pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies. About the EPIC Biotech Conference An autumnal event for 2014 when we will once again be showcasing the best of UK and European biotechs in a one day format. Some 50-60 European and UK biotech companies will be presenting and are looking for partners, investment or services. Our audience will comprise 250 - 300 delegates from the pharma, biotech, investor, CRO and service sectors. Industry keynotes will set the tone for the day and partnering will take place all day as well as informal networking. About the Therapeutic Area Partnerships (TAP) A meeting for the sharpest minds in biopharma. Since its launch eight years ago, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Oncology, Cardiovascular, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas). Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events. About BioCrea BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychiatric disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). For more information, please visit www.biocrea.com. Contact Dr. Tom Kronbach CEO, BioCrea GmbH Tel.: +49 351 / 4043 3332 Fax: +49 351 / 4043 3216 tom.kronbach@biocrea.com --------------------------------------------------------------------- 24.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 288237 24.09.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 321

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 237

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 443

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 22

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 254

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 253

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 238

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 86

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading

Top 5 Most Recently Viewed Articles

FCPT Expands Portfolio with $3.5 Million Veterinary Acquisition

Updated Category News Views 166

FCPT's Recent Acquisition Highlights Strategic Growth Four Corners Property Trust (NYSE:FCPT) has recently made headlines by acquiring a National Veterinary Associates property for $3.5 million. This acquisition signifies a notable addition to their expanding portfolio, reflecting FCPT's commitment to strategically investing in quality real estate. Details of the...

Continue Reading
Impact of National Security Probe on RH Stock Performance

Updated Category News Views 137

Unveiling the Impact of Recent National Security Investigations Shares of luxury furniture retailer RH have taken a significant hit due to President Donald Trump's announcement of a national security probe into furniture imports. This scrutiny has raised concerns across the home furnishings industry, known for its heavy reliance on global supply chains. Key Takeaways from...

Continue Reading
Understanding the Trends in Constellation Brands' Short Interest

Updated Category News Views 207

Exploring Constellation Brands' Short Interest Constellation Brands, identified by the ticker STZ, has recently reported an increase in its short percent of float, now at 10.22% since the last analysis. The company's latest data shows a total of 7.48 million shares sold short. This figure constitutes 4.42% of all available regular shares for trading. With an analysis...

Continue Reading
CTL's New Modular Monitor Aims to Redefine Flexibility

Updated Category News Views 7

CTL Unveils Innovative Modular Desktop Solutions CTL's latest move in the tech world features a new set of modular desktop products designed to cater to the education, enterprise, and government sectors. Their fresh offering—the CTL MTIP24OPS 24" Open Pluggable Specification (OPS)-Ready Monitor—comes along with two All-in-One computers operating on ChromeOS. This...

Continue Reading
Franklin Universal Trust Declares Monthly Share Distribution

Updated Category News Views 143

Franklin Universal Trust Announces Monthly Distribution Franklin Universal Trust [NYSE: FT] has declared a monthly distribution of $0.0425 per share, aimed at shareholders who are on record. This distribution is derived from net investment income and is set to be paid in the near future. Investment Objectives of the Fund The primary investment goal of Franklin Universal...

Continue Reading